Bisphosphonate treatment recommendations for oncologistsRoger von Moos
Rätisches Kantons und Regionalspital, Loestrasse 170, CH 7000, Chur, Switzerland
Oncologist 10:19-24. 2005
..Clinical studies also indicate that 50 mg oral ibandronate has an efficacy similar to that of i.v. bisphosphonates and is associated with a low incidence of adverse gastrointestinal events...
- Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
Roger von Moos
Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur 7000, Switzerland
Eur J Cancer 44:781-90. 2008
..It can cause considerable discomfort and lead to therapy interruption. Numerous approaches to HFS management have been reported, but there is no consensus...
- Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
R von Moos
Kantonsspital Graubunden, Chur, Switzerland
Ann Oncol 19:1266-70. 2008
..v. infusion of ibandronate 6 mg does not significantly alter renal function. We evaluated the effect on renal function of repeated 15-min infusions of ibandronate 6 mg in women with breast cancer and bone metastases...
- Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
Roger von Moos
Kantonsspital Graubunden, Switzerland
Onkologie 33:295-9. 2010
..A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer...
- Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
Roger von Moos
Medizinische Klinik, Onkologie und Hämatologie, Chur, Switzerland
Onkologie 33:447-50. 2010
..This current study focuses on the renal safety of the extended use of ibandronate...
- Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Richard Cathomas
Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
Support Care Cancer 18:1263-70. 2010
..No preventive strategy has definitively been established. Because this neuropathy is triggered by cold, we hypothesized that infusing oxaliplatin at 37 degrees C might reduce neuropathy...
- Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Roger von Moos
Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur, 7000, Switzerland
Support Care Cancer 16:1105-15. 2008
..In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease...
- Denosumab: first data and ongoing studies on the prevention of bone metastases
Roger von Moos
Department Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland
Recent Results Cancer Res 192:187-96. 2012
..98]; P = 0.028). This is the first study to demonstrate the clinical benefit of a bone-targeted agent in this setting. Further evaluation of denosumab in the prevention of metastatic disease is warranted and ongoing in other tumor types...
- Spontaneous pneumothorax during chemotherapy: a case report
Martin Fehr
Division of Medical Oncology, Kantonsspital Graubunden, Chur, Switzerland
Onkologie 33:527-30. 2010
..Spontaneous pneumothorax (SP) associated with malignant disease is relatively infrequent but has important diagnostic and therapeutic implications...
- Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Marc Salzberg
Pharma Brains, Basel, Switzerland
Oncology 72:147-51. 2007
..The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients...
- Drug-induced immune thrombocytopenia
Richard Cathomas
N Engl J Med 357:1870-1; author reply 1871. 2007
- Thalidomide: from tragedy to promise
Roger von Moos
Department of Internal Medicine Oncology, Kantonsspital, CH 9007 St Gallen, Switzerland
Swiss Med Wkly 133:77-87. 2003
..This review introduces the properties and putative mechanism of action of thalidomide and summarizes the most important clinical trials with this biological modifier...
